NDA 020171 · Fresenius Medcl
Delflex W/ Dextrose 4.25% Low Magnesium Low Calcium In Plastic Container
Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, Sodium Lactate · Intraperitoneal
Last checked: Nov 19, 2026Latest source record: Jan 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Aug 19, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9,299
2,122 Phase 3, 968 recruiting
FAERS reports
8,955
4,867 serious, 685 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2026.
1. INDICATIONS AND USAGE DELFLEX® is indicated in the treatment of chronic kidney failure patients being maintained on peritoneal dialysis For treatment of chronic kidney failure. ( 1 )
Mechanism: DELFLEX peritoneal dialysis solutions are hypertonic peritoneal dialysis solutions containing dextrose, a monosaccharide, as the primary osmotic agent. An osmotic gradient must be created between the peritoneal membrane and the dialysis solution in order for ultrafiltration to occur. The hypertonic concentration of glucose in DELFLEX solutions exert an osmotic pressure across the peritoneal membrane resulting in transcapillary ultrafiltration. Like other peritoneal dialysis solutions, DELFLEX solutions contain electrolytes to facilitate the correction of acid-base and electrolyte...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 19, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER · CALCIUM CHLORIDE 18.4MG/100ML; DEXTROSE 4.25GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
- DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER · CALCIUM CHLORIDE 18.4MG/100ML; DEXTROSE 1.5GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
- DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER · CALCIUM CHLORIDE 18.4MG/100ML; DEXTROSE 2.5GM/100ML; MAGNESIUM CHLORIDE 5.08MG/100ML; SODIUM CHLORIDE 538MG/100ML; SODIUM LACTATE 448MG/100ML · SOLUTION, INTRAPERITONEAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.
- Introduction of Cholera Vaccine in BangladeshPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01339845 · 240,000 participants · Start Sep 2009 · Primary completion Dec 2016
Drug: ShanChol · For: Cholera
Sites: Dhaka, Bangladesh
- Vellore Typhoid Vaccine Impact TrialPivotal-lookingCompleted
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT05500482 · 72,400 participants · Start May 1, 2023 · Primary completion Jan 31, 2026
Drug: Typhoid conjugate Vaccine · For: Typhoid Fever
Sites: Vellore, India
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Crystalloid FLUID Choices for Resuscitation of Hospitalized PatientsPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04512950 · 43,626 participants · Start Aug 15, 2016 · Primary completion Jun 13, 2020
Drug: Ringer's lactate; 0.9% saline · For: Fluid Therapy
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 7 sites in all
- Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher RiskPivotal-lookingRecruiting
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT05562609 · 40,000 participants (planned) · Start Apr 22, 2024 · Primary completion Sep 2027
Drug: Tranexamic acid · For: Postpartum Hemorrhage
Sites: Mbeya, Tanzania
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05460429 · 37,920 participants (planned) · Start Jul 30, 2022 · Primary completion Mar 15, 2023
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Chuzhou, China; Lishui, China; Quzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- peritonitis1,624
- peritonitis bacterial972
- abdominal distension614
- abdominal pain432
- death343
- malaise325
- bloody peritoneal effluent288
- dyspnoea286
- pain278
- infection274
- fluid overload267
- discomfort223
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2012 | 1 |
| 2013 | 18 |
| 2014 | 127 |
| 2015 | 456 |
| 2016 | 721 |
| 2017 | 764 |
| 2018 | 1,362 |
| 2019 | 986 |
| 2020 | 523 |
| 2021 | 834 |
| 2022 | 902 |
| 2023 | 507 |
| 2024 | 577 |
| 2025 | 705 |
| 2026 | 471 |
Recalls
13 FDA enforcement reports for this application.
Oct 14, 2026 · Class II · Ongoing
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Oct 14, 2026 · Class II · Ongoing
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Oct 14, 2026 · Class II · Ongoing
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Oct 14, 2026 · Class II · Ongoing
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Oct 14, 2026 · Class II · Ongoing
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Jun 18, 2024 · Class II · Ongoing
This product is being recalled due to the tube weld failure presents itself as a slow leak and can be difficult to detect.
Dec 28, 2023 · Class II · Ongoing
Lack of Sterility Assurance
Apr 28, 2021 · Class III · Terminated
Temperature Abuse: Product exposed to temperature outside specified limits.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Mar 10, 2026
DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
To Be Discontinued · updated Mar 10, 2026
DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
To Be Discontinued · updated Mar 10, 2026
DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
To Be Discontinued · updated Sep 10, 2026
DELFLEX, Solution, 18.4 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 46163-212-95). A business decision was made to discontinue manufacture of the drug.
To Be Discontinued · updated Mar 10, 2026
DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
To Be Discontinued · updated Mar 10, 2026
DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92). The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis.
Menegaz de Almeida A, Moraes Tamashiro F, Cavalcanti Souza ME, et al. · J Psychiatr Res 2025 · Systematic Review, Meta-Analysis
- Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults.
Conze D, Brenner C, Kruger CL · Sci Rep 2019 · Randomized Controlled Trial
- Serum chloride concentrations and outcomes in adult patients with cirrhosis: a systematic review and meta-analysis.
Kashani M, Wei L, Singh W, et al. · BMC Nephrol 2025 · Systematic Review, Meta-Analysis
- Low- versus High-Chloride Content Intravenous Solutions for Perioperative Patients: A Systematic Review and Meta-Analysis.
Song X, Wang H, Liu X, et al. · Biomed Res Int 2021 · Meta-Analysis, Systematic Review
- Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis.
Moral Nakamura D, da Graça Pinto H, Baena Elchin C, et al. · Radiother Oncol 2023 · Meta-Analysis, Systematic Review
- Traditional Chinese Medicine Injections for Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Sun W, Li J, Yan X, et al. · J Integr Complement Med 2022 · Systematic Review, Network Meta-Analysis
Sponsor: Fresenius Medcl · Also marketed as Delflex W/ Dextrose 1.5% Low Magnesium Low Calcium In Plastic Container, Delflex W/ Dextrose 2.5% Low Magnesium Low Calcium In Plastic Container
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.